Preoperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is not associated with short-term postoperative ...

Physicians need to meet patients ‘where they are’ to develop a comprehensive plan to keep weight off and live a healthy ...

Patients with T2D who undergo kidney transplants are less likely to experience organ failure and mortality if they receive ...

A recent study published in Engineering delves into the complex mechanisms of drug addiction, highlighting the crucial role of astrocytic G protein-coupled receptors (GPCRs).

GLP-1 receptor agonists were associated with better graft and patient survival. Clinical trials are needed to confirm these findings.

GLP-1 receptor agonists show promise in treating alcohol addiction by modulating reward pathways and reducing cravings, offering a novel therapeutic approach.

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR – Get Free Report) have been assigned a consensus rating of “Buy” from the ...

William Blair started coverage on shares of Structure Therapeutics (NASDAQ:GPCR – Free Report) in a research note published on Friday, Marketbeat Ratings reports. The brokerage issued an outperform ...

The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...

Among 13,711 matched pairs, GLP-1 receptor agonist users had a 10% lower risk for depression compared with DPP-4 inhibitor ...

Glucagon-like peptide-1 receptor agonists (GLP-1) drugs are a class of medications used to manage type 2 diabetes and treat ...

Northwestern University researchers have identified structural features in engineered cell receptors that correlate with variations in receptor function. Computational protein structure prediction ...